--- title: "Weekly Recap | Summit Therapeutics +5.74%, ivonescimab data stack up" type: "News" locale: "en" url: "https://longbridge.com/en/news/302954482.md" description: "Summit Therapeutics (SMMT) gained 5.74% this week to close at $15.47, while the S&P 500 fell 0.47%, leaving the stock ahead of the benchmark by about 6.21 percentage points. The week opened at $14.90, ran up to an intraday high of $16.35 on Tuesday, then faded over the second half and settled into a narrow range. The latest close sits near the 60-day average of $15.49 and below the 20-day average of $16.29. Weekly amplitude was 10.2%." datetime: "2026-10-24T07:00:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302954482.md) - [en](https://longbridge.com/en/news/302954482.md) - [zh-HK](https://longbridge.com/zh-HK/news/302954482.md) generator: "portal-rs" --- # Weekly Recap | Summit Therapeutics +5.74%, ivonescimab data stack up ## The Week Summit Therapeutics (SMMT) gained 5.74% this week to close at $15.47, while the S&P 500 fell 0.47%, leaving the stock ahead of the benchmark by about 6.21 percentage points. The week opened at $14.90, ran up to an intraday high of $16.35 on Tuesday, then faded over the second half and settled into a narrow range. The latest close sits near the 60-day average of $15.49 and below the 20-day average of $16.29. Weekly amplitude was 10.2%. ## Key Events Summit pushed forward its ivonescimab clinical pipeline through much of the week. On Monday it opened a global Phase II study of ivonescimab-based regimens in advanced clear cell renal cell carcinoma. On Wednesday the company entered a Phase II/III collaboration with ECOG-ACRIN to evaluate ivonescimab in first-line biliary tract cancer. On Thursday it said ivonescimab met the primary endpoint in a Phase II endometrial cancer study. On Friday Summit agreed with Lunit to apply the AI-powered SCOPE IO platform for tumour microenvironment analysis in immuno-oncology development. ## Analyst Ratings As of 23 October, 17 brokers cover the stock: 10 rate it buy, 1 overweight, and 6 hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target of $30.18 stands about 95.1% above the spot price of $15.47. Targets range from $11.997 to $43.584, a wide spread. Among 511 biotechnology companies, Summit ranks 40th in analyst rating. ## The Week Ahead Summit reports fiscal Q3 2026 results after the close next Tuesday, 27 October; estimates are for a loss of $0.2738 per share and revenue of $71.6k. The same day brings US durable goods orders, new home sales and consumer confidence data. The company’s full-year 2026 report is scheduled after the close on 23 February 2027. ## In Short The week’s tension was straightforward: rapid clinical progress drove SMMT ahead of the market, and the consensus target sits well above spot; yet the company has no positive P/E and a price-to-book near 19.59x, while volume ran slightly below its median. What matters next is whether the Q3 print and the pipeline keep supporting the current price. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md) ## Related News & Research - [Summit Therapeutics opens Phase II trial of ivonescimab regimens in advanced kidney cancer](https://longbridge.com/en/news/302278371.md) - [Summit Therapeutics Says Ivonescimab Meets Primary Endpoint in Phase II Endometrial Cancer Study](https://longbridge.com/en/news/302693127.md) - [Akeso Opens Global Phase II Trial of Ivonescimab in First-Line Kidney Cancer](https://longbridge.com/en/news/302287445.md) - [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md) - [VRTX: RAINIER showed strong Week 36 IgAN results; AMPLITUDE interim data are targeted for early 2027](https://longbridge.com/en/news/302935115.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**